Competitions and Markets Authority (‘CMA’) has imposed a combined fine of £35 million on 5 pharmaceutical companies, for limiting the supply of ‘Prochlorperazine’, an anti-nausea drug, used by the National Health Service (NHS). According to CMA, under the arrangement only one company was appointed as the distributor of the drug by the manufacturer of the drug and others were paid a share from its profit. Due to this arrangement, the price of Prochlorperazine surged from £6.49 to £51.68 per pack of 50 tablets between 2013 and 2017.
Strategic Consultant
